Oncodesign Precision Medicine Société anonyme (EPA:ALOPM)

France flag France · Delayed Price · Currency is EUR
0.586
-0.052 (-8.15%)
At close: Mar 6, 2026
52.21%
Market Cap 10.62M
Revenue (ttm) 1.74M
Net Income (ttm) 6.27M
Shares Out 18.12M
EPS (ttm) 0.35
PE Ratio 1.69
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 24,786
Average Volume 66,042
Open 0.610
Previous Close 0.638
Day's Range 0.574 - 0.628
52-Week Range 0.280 - 0.920
Beta -0.47
RSI 55.72
Earnings Date Apr 20, 2026

About EPA:ALOPM

Oncodesign Precision Medicine Société anonyme, a biopharmaceutical company, engages in the precision medicine business. The company’s product pipeline consist of OPM-101, a RIPK2 inhibitor for the treatment of inflammatory bowel disease and immuno-oncology; OPM-102 to treat cancer; and OPM-201, a LRRK2 inhibitor for the treatment of Parkinson’s disease. It also focuses on the development of a radiotheranostic molecule portfolio for the diagnosis and the treatment of advanced digestive cancers, as well as on developing treatment for pancreatic a... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1995
Employees 14
Stock Exchange Euronext Paris
Ticker Symbol ALOPM
Full Company Profile

Financial Performance

In 2024, EPA:ALOPM's revenue was 1.64 million, a decrease of -6.02% compared to the previous year's 1.74 million. Losses were -7.21 million, -10.89% less than in 2023.

Financial Statements

News

There is no news available yet.